Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 39,045 followers.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis #lymphoma #lymsm https://t.co/iedDfkhTio

21 Nov 2022

Reply Repost Favourite

RT @Dr_Ivanoncologo: An interesting review showed that #Brigatinib effectively treats patients with #ALK-positive non-small cell #lungcance…

04 Nov 2022

Reply Repost Favourite

An interesting review showed that #Brigatinib effectively treats patients with #ALK-positive non-small cell #lungcancer. https://t.co/o8ca77lXR9 https://t.co/o82NtGOjeZ

04 Nov 2022

Reply Repost Favourite

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis https://t.co/ZBaCpbwWNc https://t.co/IngPYhlb9F

04 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.